Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: Fibroblast-mediated pathologic bone resorption

Arthritis and Rheumatism

Volumn 58, Issue 8, 2008, Pages 2397-2408

  Tunyogi Csapo, Miklos ^a   Kis Toth, Katalin ^b   Radacs, Marianna ^c   Farkas, Balint ^a,d   Jacobs, Joshua J ^d   Finnegan, Alison ^d   Mikecz, Katalin ^d   Giant, Tibor T ^d  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ISOLATION; COMPARATIVE STUDY; CONTROLLED STUDY; FIBROBLAST; GENE; HUMAN; HUMAN CELL; INTERFERON GAMMA GENE; INTERLEUKIN 4 GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATIC DISEASE; SYNOVIOCYTE; WILD TYPE;

ANIMALS; ARTHRITIS, RHEUMATOID; BONE RESORPTION; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; OSTEOPROTEGERIN; RANK LIGAND; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49449100184     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23653     Document Type: Article

References (49)

1. Kanamaru F, Iwai H, Ikeda T, Nakajima A, Ishikawa I, Azuma M. Expression of membrane-bound and soluble receptor activator of NF-κB ligand (RANKL) in human T cells. Immunol Lett 2004;94: 239-46.
2. Lee HY, Jeon HS, Song EK, Han MK, Park SI, Lee SI, et al. CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis: evidence of NF-KB-dependent, CD40-mediated bone destruction in rheumatoid arthritis. Arthritis Rheum 2006;54:1747-58.
3. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397: 315-23.
4. Sato K, Takayanagi H. Osteoclasts, rheumatoid arthritis, and osteoimmunology [review]. Curr Opin Rheumatol 2006;18:419-26.
5. Miranda-Carus ME, Benito-Miguel M, Balsa A, Cobo-Ibanez T, Perez de Ayala C, Pascual-Salcedo D, et al. Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum 2006;54:1151-64.
6. Takahashi N, Mundy GR, Roodman GD. Recombinant human interferon-γ inhibits formation of human osteoclast-like cells. J Immunol 1986;137:3544-9.
7. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 2000;408:600-5.
8. Udagawa N, Horwood NJ, Elliott J, Mackay A, Owens J, Okamura H. Interleukin-18 (interferon-γ-inducing factor) is produced by osteoblasts and acts via granulocyte macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation. J Exp Med 1997;185:1005-12.
9. Combe B, Pope RM, Fischbach M, Darnell B, Baron S. Interleukin-2 in rheumatoid arthritis: production of and response to interleukin-2 in rheumatoid synovial fluid, synovial tissue and peripheral blood. Clin Exp Immunol 1985;59:520-8.
10. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives [editorial]. Arthritis Rheum 1997;40:598-609.
11. Hunter CA. New IL-12 family members: IL-23 and IL-27, cytokines with divergent functions [review]. Nat Rev Immunol 2005;5: 521-31.
12. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol 2001;166:4915-21.
13. Lubberts E, Joosten LA, Chabaud M, van den Bersselaar L, Oppers B, Coenen-de Roo CJ, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000;105:1697-710.
14. Abu-Amer Y. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NFκB. J Clin Invest 2001;107:1375-85.
15. Hong MH, Williams H, Jin CH, Pike JW. The inhibitory effect of interleukin-10 on mouse osteoclast formation involves novel tyrosine- phosphorylated proteins. J Bone Miner Res 2000;15:911-8.
16. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52.
17. Tran CN, Lundy SK, White PT, Endres JL, Motyl CD, Gupta R, et al. Molecular interactions between T cells and fibroblast-like synoviocytes: role of membrane tumor necrosis factor-α on cytokine-activated T cells. Am J Pathol 2007;171:1588-98.
18. Yamaguchi Y, Fujio K, Shoda H, Okamoto A, Tsuno NH, Takahashi K, et al. IL-17B and IL-17C are associated with TNF-α production and contribute to the exacerbation of inflammatory arthritis. J Immunol 2007;179:7128-36.
19. Udagawa N, Kotake S, Kamatani N, Takahashi N, Suda T. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 2002;4:281-9.
20. Walsh NC, Crotti TN, Goldring SR, Gravallese EM. Rheumatic diseases: the effects of inflammation on bone [review]. Immunol Rev 2005;208:228-51.
21. Gravallese EM. Bone destruction in arthritis [review]. Ann Rheum Dis 2002;61 Suppl 2:ii84-6.
22. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/ osteoprotegerin. Biochem Biophys Res Commun 1998;247:610-5.
23. Koreny T, Tunyogi-Csapo M, Gal I, Vermes C, Jacobs JJ, Giant TT. The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. Arthritis Rheum 2006;54:3221-32.
24. Tunyogi-Csapo M, Koreny T, Vermes C, Galante JO, Jacobs JJ, Giant TT. Role of fibroblasts and fibroblast-derived growth factors in periprosthetic angiogenesis. J Orthop Res 2007;25:1378-88.
25. Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002;17:375-87.
26. Giant TT, Mikecz K. Proteoglycan aggrecan-induced arthritis: a murine autoimmune model of rheumatoid arthritis. Methods Mol Med 2004;102:313-38.
27. Finnegan A, Grusby MJ, Kaplan CD, O'Neill SK, Eibel H, Koreny T, et al. IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. J Immunol 2002; 169: 3345-52.
28. Kaplan C, Valdez JC, Chandrasekaran R, Eibel H, Mikecz K, Giant TT, et al. Th1 and Th2 cytokines regulate proteoglycanspecific autoantibody isotypes and arthritis. Arthritis Res 2002;4: 54-8.
29. Mikecz K, Brennan FR, Kim JH, Giant TT. Anti-CD44 treatment abrogates tissue edema and leukocyte infiltration in murine arthritis. Nat Med 1995;1:558-63.
30. Pap T, Muller-Ladner U, Gay RE, Gay S. Fibroblast biology: role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2000;2:361-7.
31. Konttinen YT, Li TF, Hukkanen M, Ma J, Xu JW, Virtanen I. Fibroblast biology: signals targeting the synovial fibroblast in arthritis. Arthritis Res 2000;2:348-55.
32. Neumann E, Gay S, Muller-Ladner U. The RANK/RANKL/ osteoprotegerin system in rheumatoid arthritis: new insights from animal models [editorial]. Arthritis Rheum 2005;52:2960-7.
33. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000;275:768-75.
34. Lee CK, Lee EY, Chung SM, Mun SH, Yoo B, Moon HB. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor KB, osteoprotegerin, and receptor activator of nuclear factor κB ligand. Arthritis Rheum 2004;50:3831-43.
35. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006;12:17-25.
36. Huang W, O'Keefe RJ, Schwarz EM. Exposure to receptoractivator of NFKB ligand renders pre-osteoclasts resistant to IFN-γ by inducing terminal differentiation. Arthritis Res Ther 2003;5:R49-59.
37. Huang W, Drissi MH, O'Keefe RJ, Schwarz EM. A rapid multiparameter approach to study factors that regulate osteoclastogenesis: demonstration of the combinatorial dominant effects of TNF-α and TGF-β in RANKL-mediated osteoclastogenesis. Calcif Tissue Int 2003;73:584-93.
38. Haynes DR, Barg E, Crotti TN, Holding C, Weedon H, Atkins GJ, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxford) 2003;42:123-34.
39. Jones DH, Kong YY, Penninger JM. Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 2002;61 Suppl 2:ii32-9.
40. Zaidi M, Blair HC, Moonga BS, Abe E, Huang CL. Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J Bone Miner Res 2003;18:599-609.
41. Rogers A, Eastell R. Circulating osteoprotegerin (OPG) and receptor activator for NFKB ligand (RANKL): clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005;90:6323-31.
42. Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S, et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 2006;12:1372-9.
43. Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrazio A, Susani L, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007;39: 960-2.
44. Wei X, Zhang X, Zuscik MJ, Drissi MH, Schwarz EM, O'Keefe RJ. Fibroblasts express RANKL and support osteoclastogenesis in a COX-2-dependent manner after stimulation with titanium particles. J Bone Miner Res 2005;20:1136-48.
45. Hein GE, Meister M, Oelzner P, Franke S. sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis. Rheumatol Int 2008;28:765-9.
46. Ikeda T, Kasai M, Suzuki J, Kuroyama H, Seki S, Utsuyama M, et al. Multimerization of the receptor activator of nuclear factor-κB ligand (RANKL) isoforms and regulation of osteoclastogenesis. J Biol Chem 2003;278:47217-22.
47. Wei S, Wang MW, Teitelbaum SL, Ross FP. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-κB and mitogen-activated protein kinase signaling. J Biol Chem 2002;277: 6622-30.
48. Mirosavljevic D, Quinn JM, Elliot J, Horwood NJ, Martin TJ, Gillespie MT. T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis. J Bone Miner Res 2003;18:984-93.
49. Kim KW, Cho ML, Lee SH, Oh HJ, Kang CM, Ju JH, et al. Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation. Immunol Lett 2007;110:54-64.